Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss the signing of an MOU with St George Street Capital. Allan explains what a companion diagnostic is, what St George Street Capital do, what the proposed commercial agreement will cover and what Cizzle Biotech is looking to achieve over the coming months.
Cizzle Biotechnology is a UK based developer of A blood test for the early detection of a majority of different forms of lung cancer.
You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.
